Skip to content

Krzysztof Pyrc

Krzysztof Pyrc
Professor of the Jagiellonian University
Head of the Laboratory of Virology and Animal Facility
Phone: +48 12 664 61 21
E-mail: k.a.pyrc [AT] uj.edu.pl

Follow me on ResearchGate

Research interests

  • Virus entry
  • Novel antiviral drugs
  • Viral vectors

Grants And Awards
Show More

    • 2018. NCN Opus. Cellular proteases during coronaviral infection. PI: K Pyrc.
    • 2016: Zika virus NS3 protease. Research grant from The National Science Centre (PI: Krzysztof Pyrc). Opus funding scheme in consortia with University of Science and Technology in Krakow.
    • 2014: prof. Bassalik award for the publication "Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung".
    • 2013: Individual award of the President of the Jagiellonian University.
    • 2013: Coronavirus and the cell: dyplomatic bag. Research grant from The National Science Centre (PI: Krzysztof Pyrc). Sonata Bis funding scheme.
    • 2012: Scholarship from the Ministry of Science and Higher Education.
    • 2011: Mechanism of HCoV-NL63 / HCoV-HKU1 infection. Extension of the Iuventus Plus grant from the Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2011: Individual award of the President of the Jagiellonian University.
    • 2011: Invitation to join the Plos ONE editorial board
    • 2011: Porphyromonas gingivalis: natural defense and regulatory mechanisms. Research grant from The National Science Centre (PI: Krzysztof Pyrc)
    • 2011: Novel oncolytic vectors. Lider grant from The National Centre for Research and Development (PI: Krzysztof Pyrc).
    • 2010: Mechanism of HCoV-NL63 / HCoV-HKU1 infection. Iuventus Plus grant from the Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2010: Extension of the HOMING PROGRAMME (Reintegration Grant For Polish Scientists). Foundation for Polish Science. 09.2010-09.2011 (PI: Krzysztof Pyrc).
    • 2010: Enzymes produced by Porphyromonas gingivalis as virulence factors and potential targets for drug development against periodontitis, rheumatoid arthritis, atherosclerosis and aspiration pneumonia. Foundation for Polish Science (PI prof Jan Potempa; Aspiration pneumonia WP coordinator: Krzysztof Pyrc)
    • 2009: „HexaPrime as a new method for identification of RNA viruses” Research grant from Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2009: industrial grant together with commercial entities.
    • 2009: „Molecular Biotechnology for Health” within the EU structural funds/POIG 2.1 programme.
    • 2008 - "Polityka" Foundation Award/Stipend.
    • 2008 - HOMING PROGRAMME (Reintegration Grant For Polish Scientists) from from Foundation of Polish Science (PI: Krzysztof Pyrc).
    • 2008 - stipend within the START PROGRAMME from Foundation of Polish Science, for the most promising young researchers.
    • 2008 - PhD thesis award of the Infectious Diseases Society of the Netherlands, for the best PhD thesis in years 2005-2007 in the Netherlands.
    • 2006 - American Society for Virology Student Travel Award for the 25th "Silver Anniversary" Annual Meeting 15-19 July 2006 - University of Wisconsin-Madison.
    • 2006 - van Walree grant for working visit abroad from Royal Netherlands Academy of Arts and Sciences.
    • 2002 - Socrates / Erasmus scholarship for working visit abroad from the Jagiellonian University in Cracow on behalf of the European Comission.

    • 01.02.2017-until now: Member of the Malopolska Center of Biotechnology board.
    • 2017-until now: Member of the Committee for Evaluation of Scientific Institutions evaluation team.
    • 01.10.2016—until now: Professor of the Jagiellonian University at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 29.10.2013: Habilitation in field of microbiology. Faculty of Biology and Environmental Protection, University of Lodz, Poland.
    • 2012-2016: Member of the Committee for Evaluation of Scientific Institutions evaluation team.
    • 23.09.2012 - 30.09.2012: Scientific visit at the University of North Carolina, Chapel Hill, NC, USA
    • 01.09.2012 - 31.08.2016: Member of the Jagiellonian University Senate
    • 23-27.04.2012: Biosafety BSL3 course at the Health Protection Agency, Porton, United Kingdom
    • 04.07.2009: International Project Management Association (IPMA) certificate: "Certified Project Management Associate"
    • 01.04.2009—30.09.2016: Scientific coordinator at Molecular Biotechnology for Health project, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 01.12.2008—30.09.2016: Assistant Professor at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 01.10.2008-20.06.2008: professional studies, Project Management; Wyższa Szkola Europejska im. ks. Jozefa Tischnera, Krakow Poland
    • 01.10.2007-30.11.2008: Post-doctoral position at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 29.06.2007: PhD Thesis in field od Medical Sciences, specialization of virology. 'Virus discovery and human coronavirus NL63' Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), University of Amsterdam
    • July 2006: Radiation Safety Orientation Course, UNC at Chapel Hill, USA
    • 20.04.2006 - 14.07.2006: 3-month training at the Department of Epidemiology, University of North Carolina, Chapel Hill, United States of America.
    • 01.09.2003 - 29.07.2007: PhD student position at Departments of Human Retrovirology Academic Medical Hospital, University of Amsterdam, Amsterdam, The Netherlands
    • June 2003: Master degree thesis in the field of biotechnology, specialization of molecular biology: ' Oxidative damage of DNA in presence of etoposide and quercetin ' Faculty of Biotechnology, Krakow, Poland
    • 01.02.2003 - 31.05.2003: 4-month training at Departments of Human retrovirology in a framework of Socrates/Erasmus scholarship Academic Medical Hospital, University of Amsterdam, Amsterdam, The Netherlands
    • 1998 - 2003: Jagiellonian University, Department of General Biochemistry, Faculty of Biotechnology, Krakow, Poland
    • 1994 - 1998: Stanislaw Wyspianski High School , Krakow , Poland

    • European Society for Virology
    • American Society of Virology
    • Polish Society for Virology
    • Polish Society for Cell Biology
    • „Polityka” Scholars Association

    1. Szczepanski A, Owczarek K, Milewska A, Baster Z, Rajfur Z, Mitchell J, Pyrc K. (2018) Canine respiratory coronavirus employs caveolin-1-mediated pathway for internalization to HRT-18G cells. Veterinary Research. in press.
    2. Owczarek K, Szczepanski A, Milewska A, Baster Z, Rajfur Z, Sarna M, Pyrc K. (2018) Early events during human coronavirus OC43 entry to the cell. Scientific Reports. in press.
    3. Milewska A, Kindler E, Vkovski P, Zeglen S, Ochman M, Thiel V, Rajfur Z, Pyrc K.(2018) APOBEC3-mediated restriction of RNA virus replication. Scientific Reports. in press.
    4. A Milewska, P Nowak, K Owczarek, A Szczepanski, M Zarebski, A Hoang-Bujnowicz, K Berniak, J Wojarski, S Zeglen, Z Baster, Z Rajfur, Pyrc K (2018) Entry of human coronavirus NL63 to the cell. Journal of Virology. 92(3). pii: e01933-17.
    5. Pachota M, Klysik K, Synowiec A, Ciejka J, Szczubialka K, Pyrc K, Nowakowska M. (2017) Inhibition of herpes simplex viruses by cationic dextran derivatives. Journal of Medicinal Chemistry. 60(20):8620-8630.
    6. Burmistrz M, Rodriguez Martinez JI, Krochmal D, Staniec D, Pyrc K. (2017) crRNAs in Porphyromonas gingivalis CRISPR-Cas I-C system. Journal of Bacteriology. 199(23). pii: e00275-17.
    7. Skalniak L, Zak K, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, Pyrc K, Dömling A, Dubin G, Holak T. (2017) Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 8(42):72167-72181.
    8. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR¥, Baric RS¥ (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine. Vol. 9, Issue 396, eaal3653.
    9. Skorenski M, Pachota M, Pyrc K, Sienczyk M, Oleksyszyn J (2017) Novel Peptidyl α-Aminoalkylphosphonates as Inhibitors of Hepatitis C Virus NS3/4A Protease. Antiviral Research. 144:286-298.
    10. Ciejka J, Wolski K, Nowakowska M, Pyrc K¥, Szczubiałka K¥. (2017) Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses. Materials Science & Engineering C. 76, 735–742.
    11. Szelazek B, Kabala W, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, Burmistrz M, Florek D, Wladyka B, Pyrc K, Dubin G¥. (2017) Structural characterization of HCoV‑NL63 N-protein. Journal of Virology. 91(11). pii: e02503-16.
    12. Gruba N*, Rodriguez Martinez JI*, Grzywa R, Wysocka M, Skoreński M, Burmistrz M, Łęcka M, Lesner A¥, Sieńczyk M¥, Pyrc K¥. (2016) Substrate profiling of Zika virus NS2B-NS3 protease. FEBS Letters. 590(20):3459-3468.
    13. Szychowska M, Siwek W, Pawolski D, Karani AA, Pyrc K, Bochtler M¥ (2016) Type III CRISPR complexes from Thermus thermophilus. Acta Biochimica Polonica. 63(2):377-86.
    14. Milewska A, Kaminski K, Ciejka J, Kosowicz K, Zeglen S, Wojarski J, Nowakowska M, Szczubialka K¥, Pyrc K¥ (2016) HTCC: broad range inhibitor of coronavirus entry. PLoS One. 11(6):e0156552.
    15. Ciejka J, Milewska A, Wytrwal M, Wojarski J, Golda A, Ochman M, Nowakowska M, Szczubialka K¥, Pyrc K¥. (2016) Novel polyanions inhibiting replication of influenza viruses. Antimicrobial Agents and Chemotherapy (AAC). 60(4):1955-66.
    16. Szczubialka K., Pyrc K., Nowakowska M¥. (2016) In search for effective and definitive treatment of Herpes Simplex Virus Type 1 (HSV-1) infections. RSC Advances. 6, 1058-1075.
    17. Benedyk M., Mydel P., Płaza K., Gawron K., Milewska A., Maresz K., Koziel J., Jotwani R., Pyrc K., Potempa J¥. (2016) Gingipains: critical factors in the development of aspiration pneumonia caused by Porphyromonas gingivalis. Journal of Innate Immunity. 8(2):185-98..
    18. Burmistrz M, Dudek B, Staniec D, Rodriguez Martinez JI, Bochtler M, Potempa J, Pyrc K¥. (2015). Functional analysis of Porphyromonas gingivalis W83 CRISPR-Cas systems. Journal of Bacteriology. 197(16):2631-41.
    19. Burmistrz M, Pyrc K¥. (2015). CRISPR/Cas systems in prokaryotes. Polish Journal of Microbiology. 64(3):193-202.
    20. Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu Q, Marasco W, Baric R, Sims A¥, Pyrc K¥, Li W¥, Sui J¥. (2015). HCoV-HKU1 Spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs HE protein as a receptor-destroying enzyme. Journal of Virology. 89(14):7202-13.
    21. Zabieglo K, Majewski P, Majchrzak-Gorecka M, Wlodarczyk A, Grygier B, Zegar A, Kapinska-Mrowiecka M, Naskalska A, Pyrc K, Dubin A, Wahl S, Cichy J¥. (2015). The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps. Journal of Leukocyte Biology. 98(1):99-106.
    22. Pyrc K¥. (2015). Ludzkie koronawirusy. Postępy Nauk Medycznych. t. XXVIII, nr 4B, 2015.
    23. Naskalska A, Pyrc K¥. (2015) Virus Like Particles as Immunogens and Universal Nanocarriers. Polish Journal of Microbiology. 64(1):3-13.
    24. Zuwala K, Golda A, Kabala W, Burmistrz M, Zdzalik M, Nowak P, Kedracka-Krok S, Zarebski M, Dobrucki J, Florek D, Zeglen S, Wojarski J, Potempa J, Dubin G, Pyrc K¥. (2015) The nucleocapsid protein of human coronavirus NL63. PLoS One. 20;10(2):e0117833.
    25. Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K¥. (2014) Human coronavirus NL63 utilize heparan sulfate proteoglycans for attachment to target cells. Journal of Virology. 88(22):13221-30.
    26. Gawron K, Łazarz–Bartyzel K, Łazarz M, Stęplewska K, Pyrc K, Potempa J, Chomyszyn–Gajewska M¥. (2014) In vitro testing the potential of a novel chimeric IgG variant for inhibiting collagen fibrils formation in recurrent hereditary gingival fibromatosis. Journal of Physiology and Pharmacology. 65(4):585-91.
    27. Koziel J¥, Bryzek D, Sroka A, Maresz K, Glowczyk I, Bielecka E, Kantyka T, Pyrc K, Svoboda P, Pohl J, Potempa J. (2014) Citrullination Alters Immunomodulatory Function of LL-37 Essential for Prevention of Endotoxin-Induced Sepsis. Journal of Immunology. 2014 Apr 25.
    28. Florek D, Burmistrz M, Potempa J, Pyrc K¥. Stability of infectious human coronavirus NL63 (2014) Journal of Virological Methods. S0166-0934(14)00136-0.
    29. Maresz K, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, Gawron K, Mizgalska D, Marcinska K, Benedyk M, Pyrc K, Quirke A, Jonsson R, Alzabin S, Venables P, Nguyen K, Mydel P¥, Potempa J¥. Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD). (2013) PloS Pathogens. 9(9): e1003627.
    30. Pyrc K¥, Stozek K, Galan W, Potempa J. (2013) HexaPrime: a novel method for detection of coronaviruses. Journal of Virological Methods. 188 (1–2), 29–36.
    31. Milewska A, Ciejka J, Kaminski K, Karewicz A, Bielska D, Zeglen S, Karolak W, Nowakowska M, Potempa J, Bosch BJ, Pyrc K¥, Szczubialka K¥ (2013) Novel polymeric inhibitors of HCoV-NL63. Antiviral Research. 97(2):112-21.
    32. Kantyka T*, Pyrc K*¥, Gruca M, Smagur J, Plaza K, Guzik K, Zeglen S, Ochman M, Potempa J. (2013) Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung. Journal of Innate Immunity. 5(3):251-60.
    33. Pyrc K¥, Milewska A, Kantyka T, Sroka A, Maresz K, Kozieł J, Nguyen KA, Enghild JJ., Knudsen AD, Potempa J. (2013) Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage. Infection and Immunity, 81(1):55.
    34. Milewska A, Pyrc K¥, Human RIG-1/Mda5 and TLR3 signaling pathways and their role in antiviral response during mucosal infections, Recent Research Developments in Virology, (2012) ISBN: 978-81-7895-563-6, Transworld Research Network.
    35. Dubin G¥, Koziel J., Pyrc K., Wladyka B., Potempa J. (2013) Bacterial proteases in disease – role in intracellular survival, evasion of coagulation/fibrinolysis innate defenses, toxicoses and viral infections. Current Pharmaceutical Design. 19(6):1090-113.
    36. Dijkman R, Jebbink MF, Deijs M, Milewska A, Pyrc K, Buelow E, van der Bijl A, van der Hoek L¥. (2012) Replication dependent downregulation of cellular ACE2 protein expression by Human Coronavirus NL63. Journal of General Virology. 93(Pt 9):1924-9.
    37. Pyrc K¥, Stozek K, Wojcik K, Gawron K, Zeglen S, Karolak W, Wojarski J, Ochman M, Hubalewska-Mazgaj M, Bochenek G, Sanak M, Zembala M, Szczeklik A, Potempa J. (2012) Use of Sensitive, Broad-Spectrum Molecular Assays and Human Airway Epithelium Cultures for Detection of Respiratory Pathogens. PLoS ONE 7(3): e32582.
    38. Pyrc K¥, Strzyz P, Milewska A, Golda A, Schildgen O, Potempa J. (2011) Porphyromonas gingivalis enzymes enhance infection with human metapneumovirus in vitro. Journal of General Virology. 92(10):2324-32.
    39. Pyrc K¥, Milewska A, Potempa J. (2011) Development of loop-mediated isothermal amplification assay for detection of human coronavirus-NL63. Journal of Virological Methods. 175(1): 133-136.
    40. Golda A, Malek N, Dudek B, Zeglen S, Wojarski J, Ochman M, Kucewicz E, Zembala M, Potempa J, Pyrc K¥ (2011) Infection with human coronavirus NL63 enhances streptococcal adherence to epithelial cells. Journal of General Virology. 92(6):1358-68.
    41. Pyrc K, Sims AC, Dijkman R, Jebbink M, Long C, Deming D, Donaldson E, Vabret A, Baric R, van der Hoek L, Pickles R¥ (2010) Culturing the Unculturable: Human Coronavirus HKU1 Infects, Replicates, and Produces Progeny Virions in Human Ciliated Airway Epithelial Cell Cultures. Journal of Virology. 84(21):11255-63.
    42. Pyrc K¥ (2008) Ludzki koronawirus NL63 - Obraz kliniczny i charakterystyka molekularna. Postepy Mikrobiologii, 47(3) 257-262.
    43. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Muller MA, Kuijpers TW, Zaaijer HL, van der Hoek L¥. (2008) Human coronavirus NL63 and 229E seroconversion in children. Journal of Clinical Microbiology. 46(7):2368-73.
    44. Golda A, Pyrc K¥ (2008) Recent antiviral strategies against human coronavirus – related respiratory illness. Current Opinions in Pulmonary Medicine. 14(3):248-53.
    45. de Vries M, Pyrc K, Berkhout R, Vermeulen-Oost W, Dijkman R, Jebbink MF, Bruisten S, Berkhout B, van der Hoek L¥ (2008) Human parechovirus type 1, 3, 4, 5 and 6 detection in picornavirus cultures. Journal of Clinical Microbiology. 46(2):759-62.
    46. Pyrc K¥, Jebbink MF, Berkhout B, van der Hoek L. (2008) Detection of new viruses by VIDISCA: virus discovery based on cDNA-amplified fragment length polymorphism. in: SARS-and Other Coronaviruses, Laboratory Protocols. Methods in Molecular Biology, Vol. 454, Ed. Cavanagh, Dave, ISBN: 978-1-58829-867-6.
    47. Pyrc K, van der Hoek L¥ (2007) Human Coronavirus NL63, a Long Lost Brother. Coronaviruses: Molecular and Cellular Biology, Chapter 15, Ed. Volker Thiel, ISBN: 978-1-904455-16-5
    48. Pyrc K¥, Berkhout B, van der Hoek L.; Identification of new human coronaviruses; Expert Review of Anti-infective Therapy. 5(2):245-253.
    49. Pyrc K¥, Berkhout B, van der Hoek L (2007) Antiviral Strategies Against Human Coronaviruses; Infectious Disorders - Drug Targets. 7(1): 59-66.
    50. Dijkman R¥, Jebbink MF, Wilbrink B, Pyrc K, Zaaijer HL, Minor PD, Franklin S, Berkhout B, Thiel V, van der Hoek L (2006) Human coronavirus 229E encodes a single ORF4 protein between the spike and the envelope genes. Virology Journal. 28;3(1):106.
    51. Pyrc K, Berkhout B., and van der Hoek L¥. The novel human coronaviruses NL63 and HKU1; Journal of Virology. 81(7):3051-7.
    52. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K¥ (2006) Human coronavirus NL63 infection is associated with croup. Advances in experimental medicine and biology. 581:485-91.
    53. Pohlmann S, Gramberg T, Wegele A, Pyrc K, van der Hoek L, Berkhout B, Hofmann H¥ (2006) Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2. Advances in experimental medicine and biology. 581:281-4.
    54. Hofmann H, Marzi A, Gramberg T, Geier M, Pyrc K, van der Hoek L, Berkhout B, Pohlmann S¥ (2006) Attachment factor and receptor engagement of SARS coronavirus and human coronavirus NL63. Advances in experimental medicine and biology. 581:219-27.
    55. Piotrowski Y, van der Hoek L, Pyrc K, Berkhout B, Moll R, Hilgenfeld R¥ (2006) Nonstructural proteins of human coronavirus NL63. Advances in experimental medicine and biology. 581:97-100.
    56. Pyrc K., Dijkman R., Deng L., Jebbink MF., Ross HA., Berkhout B. van der Hoek L¥ (2006) Mosaic structure of human coronavirus NL63, one thousand years of evolution. Journal of Molecular Biology. 364(5):964-73.
    57. Schildgen O, Jebbink MF, de Vries M, Pyrc K, Dijkman R, Simon A, Muller A, Kupfer B, van der Hoek L¥ (2006) Identification of cell lines permissive for human coronavirus NL63. Journal of Virological Methods. 138(1-2):207-10.
    58. van der Hoek L., Pyrc K., Berkhout B¥ (2006) Human coronavirus NL63, a new respiratory virus. FEMS Microbiology Reviews. 30(5): 760-773.
    59. van der Hoek L, Pyrc K., Berkhout B¥ (2006) Coronavirus NL63, the new Dutch. Tijdschrift voor Infectieziekten. 1(3):108-114.
    60. Pyrc K., Bosch BJ., Berkhout B., Jebbink MF., Dijkman R., Rottier P., and van der Hoek L¥ (2006) Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle. Antimicrobial Agents and Chemotherapy. 50(6): 2000-2008.
    61. Pyrc K., Berkhout B, van der Hoek L¥ (2005) Molecular characterization of human coronavirus NL63. Recent Research in Infection and Immunity. 3(2005): 25-48 ISBN: 81-7895-182-7, Transworld Research Network.
    62. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K., Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K¥ (2005) Croup Is Associated with the Novel Coronavirus NL63., PLoS Medicine. 23;2(8):e240.
    63. Hofmann H, Pyrc K., van der Hoek L, Geier M, Berkhout B, Pohlmann S¥ (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. PNAS Proceedings of the National Academy of Sciences, USA. 102(22):7988-93.
    64. Moes E, Vijgen L, Keyaerts E, Zlateva K, Li S, Maes P, Pyrc K., Berkhout B, van der Hoek L, Van Ranst M¥ (2005) A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC infectious diseases. 1;5(1):6.
    65. Pyrc K., Jebbink MF, Berkhout B, van der Hoek L¥. (2004) Genome structure and transcriptional regulation of human coronavirus NL63. Virology Journal. 1(1):7.
    66. van der Hoek L, Pyrc K., Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Wertheim-van Dillen PM, Kaandorp J, Spaargaren J, Berkhout B¥ (2004) Identification of a new human coronavirus. Nature Medicine. 10(4):368-73.
    67. Kapiszewska M., Pyrc K. (2003) Anticancer and antiartherioslosis action of flavonoids. Vegetables and fruits in the nutrition. Medycyna i Spoleczenstwo, Acta Academiae Modrevianae, pp. 101-108.

    1. 2018. P.424871. Use of copolimers for the treatment of infections caused by HSV-1 virus.
    2. P. 416 749. The use of cationially modified dextran for the treatment of infections caused by HSV-1 virus.
    3. P. 409 016: The use of polymers in the treatment and prevention of infections caused by influenza virus.
    4. P. 409 015: The use of polymers in the treatment and prevention of infections caused by human metapneumovirus virus.
    5. PCT/PL2013/050032. Method of RNA viruses identification and its application.
    6. PCT/PL2013/00064. The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses.
    7. P 401 707. Method for identification of RNA viruses and its application.
    8. P 399 246. Application of chitosan derivatives for treatment and prophylaxis od coronaviral infection.